Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
DISEASE(S): Breast Cancer
SUBMITTER: Roberta Noberini
LAB HEAD: Tiziana Bonaldi
PROVIDER: PXD038030 | Pride | 2024-05-23
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
HF220914_RN_Magnani_1.raw | Raw | |||
HF220914_RN_Magnani_10.raw | Raw | |||
HF220914_RN_Magnani_12.raw | Raw | |||
HF220914_RN_Magnani_15.raw | Raw | |||
HF220914_RN_Magnani_19.raw | Raw |
Items per page: 5 1 - 5 of 46 |
Rosano Dalia D Sofyali Emre E Dhiman Heena H Ghirardi Chiara C Ivanoiu Diana D Heide Timon T Vingiani Andrea A Bertolotti Alessia A Pruneri Giancarlo G Canale Eleonora E Dewhurst Hannah F HF Saha Debjani D Slaven Neil N Barozzi Iros I Li Tong T Zemlyanskiy Grigory G Phillips Henry H James Chela C Győrffy Balázs B Lynn Claire C Cresswell George D GD Rehman Farah F Noberini Roberta R Bonaldi Tiziana T Sottoriva Andrea A Magnani Luca L
Cancer discovery 20240501 5
Patients with estrogen receptor-positive breast cancer receive adjuvant endocrine therapies (ET) that delay relapse by targeting clinically undetectable micrometastatic deposits. Yet, up to 50% of patients relapse even decades after surgery through unknown mechanisms likely involving dormancy. To investigate genetic and transcriptional changes underlying tumor awakening, we analyzed late relapse patients and longitudinally profiled a rare cohort treated with long-term neoadjuvant ETs until progr ...[more]